(BMY) Bristol-Myers Squibb - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1101221083
Stock: Cancer Drugs, Blood Disorders, Autoimmune Diseases, Heart Medications
Total Rating 42
Risk 72
Buy Signal -0.30
| Risk 5d forecast | |
|---|---|
| Volatility | 28.7% |
| Relative Tail Risk | -7.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -11.92 |
| Character TTM | |
|---|---|
| Beta | 0.426 |
| Beta Downside | 0.520 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.94% |
| CAGR/Max DD | 0.02 |
EPS (Earnings per Share)
Revenue
Description: BMY Bristol-Myers Squibb March 05, 2026
Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The companys portfolio spans oncology, hematology, immunology, and cardiovascular diseases.
Key products include Opdivo (oncology), Orencia (immunology), and Eliquis (cardiovascular). The pharmaceutical sector is characterized by high research and development costs and lengthy drug approval processes.
BMY distributes its products through wholesalers, distributors, specialty pharmacies, and direct sales to healthcare providers and government agencies. The business model relies heavily on patent protection for its pipeline and existing drugs.
Further research on ValueRay can provide deeper insights into BMYs competitive landscape and financial performance.
Headlines to watch out for
- Opdivo sales growth impacts oncology revenue
- Eliquis patent expiry threatens cardiovascular sales
- Pipeline success crucial for future revenue streams
- Regulatory approvals drive new product launches
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 7.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -0.79 > 1.0 |
| NWC/Revenue: 12.39% < 20% (prev 12.43%; Δ -0.04% < -1%) |
| CFO/TA 0.16 > 3% & CFO 14.16b > Net Income 7.05b |
| Net Debt (36.93b) to EBITDA (14.54b): 2.54 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.20% < -2% |
| Gross Margin: 67.65% > 18% (prev 0.57%; Δ 6.71k% > 0.5%) |
| Asset Turnover: 52.77% > 50% (prev 52.16%; Δ 0.62% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBITDA TTM 14.54b / Interest Expense TTM 1.51b) |
Altman Z'' 2.06
| A: 0.07 (Total Current Assets 29.39b - Total Current Liabilities 23.42b) / Total Assets 90.04b |
| B: 0.19 (Retained Earnings 16.90b / Total Assets 90.04b) |
| C: 0.12 (EBIT TTM 10.69b / Avg Total Assets 91.32b) |
| D: 0.22 (Book Value of Equity 15.66b / Total Liabilities 71.53b) |
| Altman-Z'' Score: 2.06 = BBB |
Beneish M -3.26
| DSRI: 1.01 (Receivables 14.53b/14.42b, Revenue 48.19b/48.30b) |
| GMI: 0.84 (GM 67.65% / 56.80%) |
| AQI: 0.97 (AQ_t 0.57 / AQ_t-1 0.59) |
| SGI: 1.00 (Revenue 48.19b / 48.30b) |
| TATA: -0.08 (NI 7.05b - CFO 14.16b) / TA 90.04b) |
| Beneish M-Score: -3.26 (Cap -4..+1) = AA |
What is the price of BMY shares?
As of March 15, 2026, the stock is trading at USD 59.98 with a total of 9,043,088 shares traded.
Over the past week, the price has changed by -2.01%, over one month by -2.73%, over three months by +10.11% and over the past year by +2.96%.
Over the past week, the price has changed by -2.01%, over one month by -2.73%, over three months by +10.11% and over the past year by +2.96%.
Is BMY a buy, sell or hold?
Bristol-Myers Squibb has received a consensus analysts rating of 3.37.
Therefor, it is recommend to hold BMY.
- StrongBuy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 3.6% |
| Analysts Target Price | 62.2 | 3.6% |
BMY Fundamental Data Overview March 10, 2026
P/E Trailing = 17.4224
P/E Forward = 9.6712
P/S = 2.562
P/B = 6.6464
P/EG = 2.2562
Revenue TTM = 48.19b USD
EBIT TTM = 10.69b USD
EBITDA TTM = 14.54b USD
Long Term Debt = 42.85b USD (from longTermDebt, last quarter)
Short Term Debt = 2.46b USD (from shortTermDebt, last quarter)
Debt = 47.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.93b USD (from netDebt column, last quarter)
Enterprise Value = 160.40b USD (123.47b + Debt 47.14b - CCE 10.21b)
Interest Coverage Ratio = 7.08 (Ebit TTM 10.69b / Interest Expense TTM 1.51b)
EV/FCF = 12.49x (Enterprise Value 160.40b / FCF TTM 12.85b)
FCF Yield = 8.01% (FCF TTM 12.85b / Enterprise Value 160.40b)
FCF Margin = 26.65% (FCF TTM 12.85b / Revenue TTM 48.19b)
Net Margin = 14.63% (Net Income TTM 7.05b / Revenue TTM 48.19b)
Gross Margin = 67.65% ((Revenue TTM 48.19b - Cost of Revenue TTM 15.59b) / Revenue TTM)
Gross Margin QoQ = 67.23% (prev 71.89%)
Tobins Q-Ratio = 1.78 (Enterprise Value 160.40b / Total Assets 90.04b)
Interest Expense / Debt = 0.11% (Interest Expense 51.0m / Debt 47.14b)
Taxrate = 26.12% (384.0m / 1.47b)
NOPAT = 7.89b (EBIT 10.69b * (1 - 26.12%))
Current Ratio = 1.26 (Total Current Assets 29.39b / Total Current Liabilities 23.42b)
Debt / Equity = 2.55 (Debt 47.14b / totalStockholderEquity, last quarter 18.47b)
Debt / EBITDA = 2.54 (Net Debt 36.93b / EBITDA 14.54b)
Debt / FCF = 2.88 (Net Debt 36.93b / FCF TTM 12.85b)
Total Stockholder Equity = 17.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.72% (Net Income 7.05b / Total Assets 90.04b)
RoE = 39.27% (Net Income TTM 7.05b / Total Stockholder Equity 17.96b)
RoCE = 17.57% (EBIT 10.69b / Capital Employed (Equity 17.96b + L.T.Debt 42.85b))
RoIC = 11.92% (NOPAT 7.89b / Invested Capital 66.21b)
WACC = 5.44% (E(123.47b)/V(170.61b) * Re(7.49%) + D(47.14b)/V(170.61b) * Rd(0.11%) * (1-Tc(0.26)))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.20%
[DCF] Terminal Value 87.00% ; FCFF base≈13.28b ; Y1≈14.24b ; Y5≈17.31b
[DCF] Fair Price = 233.5 (EV 512.48b - Net Debt 36.93b = Equity 475.55b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -12.32 | EPS CAGR: -12.29% | SUE: -1.59 | # QB: 0
Revenue Correlation: 59.09 | Revenue CAGR: 1.90% | SUE: 1.02 | # QB: 9
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.000 | Chg30d=+0.013 | Revisions Net=+5 | Analysts=19
EPS current Year (2026-12-31): EPS=6.27 | Chg7d=+0.000 | Chg30d=+0.058 | Revisions Net=+16 | Growth EPS=+1.9% | Growth Revenue=-2.2%
EPS next Year (2027-12-31): EPS=6.13 | Chg7d=+0.000 | Chg30d=+0.119 | Revisions Net=+10 | Growth EPS=-2.3% | Growth Revenue=-2.9%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.2% (Discount Rate 7.9% - Earnings Yield 5.7%)
[Growth] Growth Spread = -5.2% (Analyst -3.0% - Implied 2.2%)
P/E Forward = 9.6712
P/S = 2.562
P/B = 6.6464
P/EG = 2.2562
Revenue TTM = 48.19b USD
EBIT TTM = 10.69b USD
EBITDA TTM = 14.54b USD
Long Term Debt = 42.85b USD (from longTermDebt, last quarter)
Short Term Debt = 2.46b USD (from shortTermDebt, last quarter)
Debt = 47.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.93b USD (from netDebt column, last quarter)
Enterprise Value = 160.40b USD (123.47b + Debt 47.14b - CCE 10.21b)
Interest Coverage Ratio = 7.08 (Ebit TTM 10.69b / Interest Expense TTM 1.51b)
EV/FCF = 12.49x (Enterprise Value 160.40b / FCF TTM 12.85b)
FCF Yield = 8.01% (FCF TTM 12.85b / Enterprise Value 160.40b)
FCF Margin = 26.65% (FCF TTM 12.85b / Revenue TTM 48.19b)
Net Margin = 14.63% (Net Income TTM 7.05b / Revenue TTM 48.19b)
Gross Margin = 67.65% ((Revenue TTM 48.19b - Cost of Revenue TTM 15.59b) / Revenue TTM)
Gross Margin QoQ = 67.23% (prev 71.89%)
Tobins Q-Ratio = 1.78 (Enterprise Value 160.40b / Total Assets 90.04b)
Interest Expense / Debt = 0.11% (Interest Expense 51.0m / Debt 47.14b)
Taxrate = 26.12% (384.0m / 1.47b)
NOPAT = 7.89b (EBIT 10.69b * (1 - 26.12%))
Current Ratio = 1.26 (Total Current Assets 29.39b / Total Current Liabilities 23.42b)
Debt / Equity = 2.55 (Debt 47.14b / totalStockholderEquity, last quarter 18.47b)
Debt / EBITDA = 2.54 (Net Debt 36.93b / EBITDA 14.54b)
Debt / FCF = 2.88 (Net Debt 36.93b / FCF TTM 12.85b)
Total Stockholder Equity = 17.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.72% (Net Income 7.05b / Total Assets 90.04b)
RoE = 39.27% (Net Income TTM 7.05b / Total Stockholder Equity 17.96b)
RoCE = 17.57% (EBIT 10.69b / Capital Employed (Equity 17.96b + L.T.Debt 42.85b))
RoIC = 11.92% (NOPAT 7.89b / Invested Capital 66.21b)
WACC = 5.44% (E(123.47b)/V(170.61b) * Re(7.49%) + D(47.14b)/V(170.61b) * Rd(0.11%) * (1-Tc(0.26)))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.20%
[DCF] Terminal Value 87.00% ; FCFF base≈13.28b ; Y1≈14.24b ; Y5≈17.31b
[DCF] Fair Price = 233.5 (EV 512.48b - Net Debt 36.93b = Equity 475.55b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -12.32 | EPS CAGR: -12.29% | SUE: -1.59 | # QB: 0
Revenue Correlation: 59.09 | Revenue CAGR: 1.90% | SUE: 1.02 | # QB: 9
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.000 | Chg30d=+0.013 | Revisions Net=+5 | Analysts=19
EPS current Year (2026-12-31): EPS=6.27 | Chg7d=+0.000 | Chg30d=+0.058 | Revisions Net=+16 | Growth EPS=+1.9% | Growth Revenue=-2.2%
EPS next Year (2027-12-31): EPS=6.13 | Chg7d=+0.000 | Chg30d=+0.119 | Revisions Net=+10 | Growth EPS=-2.3% | Growth Revenue=-2.9%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.2% (Discount Rate 7.9% - Earnings Yield 5.7%)
[Growth] Growth Spread = -5.2% (Analyst -3.0% - Implied 2.2%)